Taysha Gene Therapies to Release Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 4

Rhea-AI Summary

Taysha Gene Therapies (Nasdaq: TSHA) will report third quarter 2025 financial results for the period ended September 30, 2025, and will host a corporate update conference call and webcast on Tuesday, November 4, 2025 at 8:30 AM ET.

The event includes a toll-free dial-in, international number, and a webcast at https://ir.tayshagtx.com/news-events/events-presentations. Conference ID is TAYSHA. The call time in Central Time is 7:30 AM CT.

News Market Reaction

+2.25%

1 alert

+2.25% News Effect

On the day this news was published, TSHA gained 2.25%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

DALLAS, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the third quarter ended September 30, 2025, and host a corporate update conference call and webcast on Tuesday, November 4, 2025, at 8:30 AM Eastern Time.

Conference Call Details
Tuesday, November 4, at 8:30 AM Eastern Time / 7:30 AM Central Time
Toll Free: 800-245-3047
International: 203-518-9765
Conference ID: TAYSHA
Webcast: https://ir.tayshagtx.com/news-events/events-presentations

About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit http://www.tayshagtx.com.

Company Contact:
Hayleigh Collins
Senior Director, Corporate Communications and Investor Relations
Taysha Gene Therapies, Inc.
hcollins@tayshagtx.com

Media Contact:
Carolyn Hawley
Inizio Evoke
carolyn.hawley@inizioevoke.com

FAQ

When will Taysha (TSHA) release its Q3 2025 financial results?

Taysha will release third quarter 2025 results for the period ended September 30, 2025 and discuss them on November 4, 2025.

What time is the Taysha (TSHA) conference call and webcast on November 4, 2025?

The conference call is scheduled for 8:30 AM Eastern Time (7:30 AM Central Time) on November 4, 2025.

How can I join the Taysha (TSHA) November 4, 2025 webcast?

Join the webcast at https://ir.tayshagtx.com/news-events/events-presentations using the live event link.

What dial-in numbers are provided for the Taysha (TSHA) investor call on November 4, 2025?

Toll free dial-in is 800-245-3047; international dial-in is 203-518-9765 with Conference ID TAYSHA.

Will Taysha (TSHA) discuss clinical updates during the November 4, 2025 call?

The company said the event is a corporate update; investors should listen to the November 4 webcast for any clinical program commentary.

Where can investors find the Taysha (TSHA) replay after the November 4, 2025 call?

A replay is typically posted on the investor events page at https://ir.tayshagtx.com/news-events/events-presentations after the call.